Thales, European Leader in Quantum Physics and Artificial Intelligence, Opens InnovDays 2019
27.11.2019 20:36:00 EET | Business Wire | Press release
Thales launched InnovDays in 2012 as a way for its customers and partners to gain exclusive insights into the technological excellence of its research facilities. Since then, successive InnovDays events have turned the spotlight on the latest technological innovations developed by more than 29,500 Thales engineers and researchers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191127005575/en/
Thales InnovDays 2019 (Photo: Thales)
InnovDays: building a trusted future through science
InnovDays is a reflection of Thales's objective of leveraging science and high technology to build a future we can all trust. By harnessing the unprecedented precision and power of quantum physics and augmenting the performance of its systems thanks to artificial intelligence, Thales is developing the new generation of technologies that will shape the world of tomorrow.
"InnovDays is an illustration of Thales's outstanding technological capabilities and the passion displayed by our 29,500 engineers for helping our customers step up to society's major challenges through innovation." Marko Erman, Chief Technology Officer.
As an expert in critical systems, Thales is conducting in-depth research into both digital technologies and deep tech solutions to develop a portfolio of products based on a common core of technological building blocks. At InnovDays on 27, 28 and 29 November 2019, Thales will present a total of 70 practical applications of this research centred around the following themes:
Round tables:
-
Thursday 28 November:
- 8.30 am: How can we make AI trustable?
- 1.30 pm: Sovereignty in the digital age
-
Friday 29 November:
- 8.30 am: High tech and climate change: friend or foe?
- 11.00 am: The strategy and the future of air transport
- 1.30 pm: The second quantum revolution starts now!
Star guests from the world of science and industry will be taking part in these round table sessions, including Albert Fert (Nobel Prize in Physics 2007), Jean-Marc Jancovici (Founder and President of The Shift Project), Alexandre de Juniac (IATA Director General and CEO) and Pascale Senellart (research director at the Centre for Nanoscience and Nanotechnology, Paris-Saclay University, Paris-Sud University, CNRS).
Proposed press tours at InnovDays 2019
- Tomorrow's cities
- The future of transport
- Biometrics
- The Cloud
- Big Data
- Tomorrow's connectivity in the civil world
- Tomorrow's connectivity in the world of defence
- Air defence of the future
- Land and naval defence of the future
- The augmented soldier
- Secure identities and data for citizens and businesses
|
On 27, 28 and 29 November 2019, the Thales YouTube channel will feature live coverage of the round table sessions and some of the most popular demonstrations. |
From sensors that are up to 10,000 more accurate to ultra-secure communications, quantum technologies are set to push back the boundaries of physics and unleash previously unexploited properties of matter.
An aircraft flying from Paris to New York with only an inertial navigation system to guide it could determine its location to within a few kilometres. With future quantum sensors, it could land with a precision of within a metre. In other fields, quantum sensors could detect tumours that are invisible today, or provide a basis for developing new sources of energy.
Quantum physics relies on radically new concepts and ways of manipulating matter. Quantum sensors, like quantum communications and quantum computing, are currently under the microscope in the laboratories operated by Thales and its academic partners (CNRS, Université Paris-Saclay, etc.) at the Saclay research and technology cluster, south of Paris.
On 26 November 2019, Thales and its academic and research partners are organising a presentation at Saclay to highlight European excellence in quantum research: from cold atoms to flawed diamonds and superconductors, scientific progress in quantum physics has the potential to harness unexploited properties of matter and unleash a whole host of new opportunities.
Thales is working on these new properties to develop the next generation of quantum sensors, relying on the exact same technological building blocks as quantum computers. Quantum encryption too, could soon lead to communication systems that are completely secure and trustworthy.
Thales has also been selected to take part in the European OPENQKD initiative as part of the Austrian Institute of Technology (AIT) consortium chosen by the European Commission to install infrastructure in several European countries to test quantum communication networks.
Navigating intelligently among millions of aircraft movements: Thales presents the brain of tomorrow's aircraft.
Ultimately, quantum technologies will provide untold benefits for avionics systems, including order-of-magnitude improvements in navigation precision. But the immediate truth is that solutions are needed now to deal with the growth in air traffic, which is expected to have doubled by 2030.
This is the thinking behind PureFlyt, developed by Thales as the brain of tomorrow's aircraft, a fully connected cockpit that will significantly increase aircraft performance.
PureFlyt will be unveiled in Toulouse on 25 November. One of the core innovations that makes PureFlyt a game-changer is its ability to draw on both onboard and open-world data, such as weather information, so that the aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and a better flying experience for both passengers and crew.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
Thales Group
Download photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005575/en/
Contact information
PRESS
Thales, Media relations
Cédric Leurquin
+33 (0)1 57 77 90 93
cedric.leurquin@thalesgroup.com
Thales, Media relations
Alice Pruvot
+331 57 77 89 52
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
